Effects of acute topiramate dosing on methamphetamine-induced subjective mood

Bankole A. Johnson, John D Roache, Nassima Ait-Daoud, Lynda T. Wells, Christopher L. Wallace, Michael A Dawes, Lei Liu, Xin Qun Wang

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Clinical studies have shown that topiramate, a sulphamate-substituted fructopyranose derivative, might be an efficacious treatment for alcohol dependence, smoking cessation within an alcohol-dependent population, and cocaine dependence. Mechanistically, topiramate's therapeutic effects have been hypothesized to be due to inhibition of cortico-mesolimbic dopamine function, the primary substrate that governs the acquisition, maintenance, and reinstatement of goal-directed behaviour towards seeking abused drugs. Predicated on this hypothesis, we tested in 10 methamphetamine-dependent individuals (three females) whether low- or high-dose (15 or 30 mg i.v.) methamphetamine-induced positive subjective effects and reinforcement can be antagonized by low- or high-dose (100 or 200 mg orally) topiramate using a placebo-controlled, cross-over, factorial design. Methamphetamine administration was associated with orderly, prototypical, and significant increases on measures of stimulation, euphoria, craving, and reinforcement; however, some dysphoric symptoms also emerged. Topiramate alone showed a non-significant trend towards mild reductions in positive mood and reinforcement; yet topiramate appeared to accentuate the appreciation of methamphetamine-induced stimulation and euphoria significantly, but not craving or reinforcement. The experimental combination of topiramate and methamphetamine appeared to be safe and well tolerated, with few adverse events. Acute dosing with up to 200 mg topiramate appears to enhance, rather than attenuate, the positive subjective effects of methamphetamine. Perhaps this indicates a partial inhibition of methamphetamine's reinforcing effects. Thus, testing chronically administered or higher doses, or both, of topiramate would be necessary to determine conclusively whether or not it can attenuate the positive subjective and reinforcing effects of methamphetamine.

Original languageEnglish (US)
Pages (from-to)85-98
Number of pages14
JournalInternational Journal of Neuropsychopharmacology
Volume10
Issue number1
DOIs
StatePublished - Feb 2007

Fingerprint

Methamphetamine
Cocaine-Related Disorders
topiramate
Therapeutic Uses
Smoking Cessation
Cross-Over Studies
Alcoholism
Dopamine
Placebos
Maintenance
Alcohols
Reinforcement (Psychology)
Pharmaceutical Preparations

Keywords

  • Craving
  • Euphoria
  • GABA
  • Glutamate
  • Humans
  • Kinetic
  • Methamphetamine
  • Mood
  • Reward
  • Topiramate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Neuropsychology and Physiological Psychology
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Effects of acute topiramate dosing on methamphetamine-induced subjective mood. / Johnson, Bankole A.; Roache, John D; Ait-Daoud, Nassima; Wells, Lynda T.; Wallace, Christopher L.; Dawes, Michael A; Liu, Lei; Wang, Xin Qun.

In: International Journal of Neuropsychopharmacology, Vol. 10, No. 1, 02.2007, p. 85-98.

Research output: Contribution to journalArticle

Johnson, BA, Roache, JD, Ait-Daoud, N, Wells, LT, Wallace, CL, Dawes, MA, Liu, L & Wang, XQ 2007, 'Effects of acute topiramate dosing on methamphetamine-induced subjective mood', International Journal of Neuropsychopharmacology, vol. 10, no. 1, pp. 85-98. https://doi.org/10.1017/S1461145705006401
Johnson, Bankole A. ; Roache, John D ; Ait-Daoud, Nassima ; Wells, Lynda T. ; Wallace, Christopher L. ; Dawes, Michael A ; Liu, Lei ; Wang, Xin Qun. / Effects of acute topiramate dosing on methamphetamine-induced subjective mood. In: International Journal of Neuropsychopharmacology. 2007 ; Vol. 10, No. 1. pp. 85-98.
@article{bf7591fd79c746789ceb8d742648bfa5,
title = "Effects of acute topiramate dosing on methamphetamine-induced subjective mood",
abstract = "Clinical studies have shown that topiramate, a sulphamate-substituted fructopyranose derivative, might be an efficacious treatment for alcohol dependence, smoking cessation within an alcohol-dependent population, and cocaine dependence. Mechanistically, topiramate's therapeutic effects have been hypothesized to be due to inhibition of cortico-mesolimbic dopamine function, the primary substrate that governs the acquisition, maintenance, and reinstatement of goal-directed behaviour towards seeking abused drugs. Predicated on this hypothesis, we tested in 10 methamphetamine-dependent individuals (three females) whether low- or high-dose (15 or 30 mg i.v.) methamphetamine-induced positive subjective effects and reinforcement can be antagonized by low- or high-dose (100 or 200 mg orally) topiramate using a placebo-controlled, cross-over, factorial design. Methamphetamine administration was associated with orderly, prototypical, and significant increases on measures of stimulation, euphoria, craving, and reinforcement; however, some dysphoric symptoms also emerged. Topiramate alone showed a non-significant trend towards mild reductions in positive mood and reinforcement; yet topiramate appeared to accentuate the appreciation of methamphetamine-induced stimulation and euphoria significantly, but not craving or reinforcement. The experimental combination of topiramate and methamphetamine appeared to be safe and well tolerated, with few adverse events. Acute dosing with up to 200 mg topiramate appears to enhance, rather than attenuate, the positive subjective effects of methamphetamine. Perhaps this indicates a partial inhibition of methamphetamine's reinforcing effects. Thus, testing chronically administered or higher doses, or both, of topiramate would be necessary to determine conclusively whether or not it can attenuate the positive subjective and reinforcing effects of methamphetamine.",
keywords = "Craving, Euphoria, GABA, Glutamate, Humans, Kinetic, Methamphetamine, Mood, Reward, Topiramate",
author = "Johnson, {Bankole A.} and Roache, {John D} and Nassima Ait-Daoud and Wells, {Lynda T.} and Wallace, {Christopher L.} and Dawes, {Michael A} and Lei Liu and Wang, {Xin Qun}",
year = "2007",
month = "2",
doi = "10.1017/S1461145705006401",
language = "English (US)",
volume = "10",
pages = "85--98",
journal = "The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)",
issn = "1461-1457",
publisher = "Cambridge University Press",
number = "1",

}

TY - JOUR

T1 - Effects of acute topiramate dosing on methamphetamine-induced subjective mood

AU - Johnson, Bankole A.

AU - Roache, John D

AU - Ait-Daoud, Nassima

AU - Wells, Lynda T.

AU - Wallace, Christopher L.

AU - Dawes, Michael A

AU - Liu, Lei

AU - Wang, Xin Qun

PY - 2007/2

Y1 - 2007/2

N2 - Clinical studies have shown that topiramate, a sulphamate-substituted fructopyranose derivative, might be an efficacious treatment for alcohol dependence, smoking cessation within an alcohol-dependent population, and cocaine dependence. Mechanistically, topiramate's therapeutic effects have been hypothesized to be due to inhibition of cortico-mesolimbic dopamine function, the primary substrate that governs the acquisition, maintenance, and reinstatement of goal-directed behaviour towards seeking abused drugs. Predicated on this hypothesis, we tested in 10 methamphetamine-dependent individuals (three females) whether low- or high-dose (15 or 30 mg i.v.) methamphetamine-induced positive subjective effects and reinforcement can be antagonized by low- or high-dose (100 or 200 mg orally) topiramate using a placebo-controlled, cross-over, factorial design. Methamphetamine administration was associated with orderly, prototypical, and significant increases on measures of stimulation, euphoria, craving, and reinforcement; however, some dysphoric symptoms also emerged. Topiramate alone showed a non-significant trend towards mild reductions in positive mood and reinforcement; yet topiramate appeared to accentuate the appreciation of methamphetamine-induced stimulation and euphoria significantly, but not craving or reinforcement. The experimental combination of topiramate and methamphetamine appeared to be safe and well tolerated, with few adverse events. Acute dosing with up to 200 mg topiramate appears to enhance, rather than attenuate, the positive subjective effects of methamphetamine. Perhaps this indicates a partial inhibition of methamphetamine's reinforcing effects. Thus, testing chronically administered or higher doses, or both, of topiramate would be necessary to determine conclusively whether or not it can attenuate the positive subjective and reinforcing effects of methamphetamine.

AB - Clinical studies have shown that topiramate, a sulphamate-substituted fructopyranose derivative, might be an efficacious treatment for alcohol dependence, smoking cessation within an alcohol-dependent population, and cocaine dependence. Mechanistically, topiramate's therapeutic effects have been hypothesized to be due to inhibition of cortico-mesolimbic dopamine function, the primary substrate that governs the acquisition, maintenance, and reinstatement of goal-directed behaviour towards seeking abused drugs. Predicated on this hypothesis, we tested in 10 methamphetamine-dependent individuals (three females) whether low- or high-dose (15 or 30 mg i.v.) methamphetamine-induced positive subjective effects and reinforcement can be antagonized by low- or high-dose (100 or 200 mg orally) topiramate using a placebo-controlled, cross-over, factorial design. Methamphetamine administration was associated with orderly, prototypical, and significant increases on measures of stimulation, euphoria, craving, and reinforcement; however, some dysphoric symptoms also emerged. Topiramate alone showed a non-significant trend towards mild reductions in positive mood and reinforcement; yet topiramate appeared to accentuate the appreciation of methamphetamine-induced stimulation and euphoria significantly, but not craving or reinforcement. The experimental combination of topiramate and methamphetamine appeared to be safe and well tolerated, with few adverse events. Acute dosing with up to 200 mg topiramate appears to enhance, rather than attenuate, the positive subjective effects of methamphetamine. Perhaps this indicates a partial inhibition of methamphetamine's reinforcing effects. Thus, testing chronically administered or higher doses, or both, of topiramate would be necessary to determine conclusively whether or not it can attenuate the positive subjective and reinforcing effects of methamphetamine.

KW - Craving

KW - Euphoria

KW - GABA

KW - Glutamate

KW - Humans

KW - Kinetic

KW - Methamphetamine

KW - Mood

KW - Reward

KW - Topiramate

UR - http://www.scopus.com/inward/record.url?scp=33846269647&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846269647&partnerID=8YFLogxK

U2 - 10.1017/S1461145705006401

DO - 10.1017/S1461145705006401

M3 - Article

C2 - 16448579

AN - SCOPUS:33846269647

VL - 10

SP - 85

EP - 98

JO - The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

JF - The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP)

SN - 1461-1457

IS - 1

ER -